AUTHOR=Meng Mi , Yu Bo , Luo Jie , Bai Yuju , Li Lin , Chen Shicheng , He Sisi , Ma Hu 

TITLE=Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma

JOURNAL=Frontiers in Oncology

VOLUME=14

YEAR=2024

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1326006

DOI=10.3389/fonc.2024.1326006

ISSN=2234-943X

ABSTRACT=<p>Thymic carcinoma (TC) is an uncommon type of thymic epithelial tumors. Patients with relapsed or refractory TCs have a poor prognosis. Immune checkpoint inhibitor monotherapy can be applied as a second-line treatment for such cases. This study reported a TC patient who did not respond to conventional chemotherapy and radiotherapy but achieved prolonged partial remission lasting 17 months following the third-line treatment with anti-programmed cell death-1 inhibitor sintilimab. This patient did not experience any serious side effects associated with sintilimab treatment. The above results demonstrated that sintilimab could be a feasible therapeutic option for refractory TC patients.</p>